Our CEO Ian Wilson will be at the Biotech Showcase on January 9–11 in San Francisco. Contact him through the partnering system to arrange a meeting.
Biotech Showcase
read more
News
EM Imaging Win Best Emerging Medtech Company Award
OBN Awards 2016 Winners Recognised at Industry Leading EventEM Imaging CEO Ian Wilson celebrates wining the Best Emerging Medtech Company Award at OBN 2016. At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company Award. The...
Bio-Europe November 7–9, 2016
Ian Wilson and Diane Harbison will be attending Bio-Europe in Cologne. We are interested in speaking to potential investors for our Series B funding round or in opportunities for collaboration using our optical imaging agents. If you are interested in meeting them, please request a meeting through...
Edinburgh Molecular Imaging are part of a EPSRC funded consortium
Edinburgh Molecular Imaging is part of an EPSRC funded consortium, led by Dr Jon Shephard of Heriot-Watt University in collaboration with Professor David Jayne from the University of Leeds to develop a revolutionary new bowel cancer surgery tool that will enable surgeons to carry out operations...
EM Imaging at EIE16
On 12th May, EM Imaging took part to the EIE16 investor showcase (http://www.eie-invest.com/), along with 60 companies across the Life Sciences, Energy and ICT sectors. With more than 900 guests, the event was an absolute success. EM Imaging had the opportunity to pitch in front of potential...
Edinburgh Molecular Imaging and Mauna Kea Technologies Announce Clinical Molecular Imaging Collaboration
Edinburgh and Paris, April 6th, 2016 – Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea's...
Edinburgh Molecular imaging Ltd awarded Innovate UK grant to qualify the role of EMI-137 in colorectal cancer lesion detection
Edinburgh Molecular imaging Ltd (EM Imaging) announced today that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase the development and adoption of...
EM Imaging finalist at Pitch@Palace
EM Imaging has been selected as one of the 14 teams that will Pitch on Monday 7th March, 2016 at St. James's Palace. In addition, there will be a Peoples Choice vote and we would appreciate if our followers could vote for us at the following link. ow.ly/YI6dN
Edinburgh Molecular Imaging to Pitch@Palace
Edinburgh Molecular Imaging have been announced as finalists at the Duke of York’s 'Pitch at the Palace' competition, which is designed to help entrepreneurs develop their business ideas. The team will pitch to HRH Duke of York and 300 business people at St James’s Palace on 7...
EM Imaging obtains global licence for optical agent that detects cancer early
Edinburgh, United Kingdom, 16 th September, 2015 - Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer. EM Imaging, a company which develops and...